Investment activities surrounding
Regeneron Pharmaceuticals (NASDAQ:REGN) have surged lately. Multiple high-profile investors like
Balentine LLC,
Cwm LLC,
Bailard Inc., and
Wealthfront Advisers LLC have adjusted their positions in the company. Furthermore, REGN's
trading volume spiked by 30.57%, but the stock has seen a dip, falling 22.6% year-to-date. The firm's pipeline development is significantly progressing with its drug
Dupixent® receiving US FDA approval, a potential game-changer. Moreover, development of
RENG7508 and studies on anticoagulant alternatives put the company as an entrant in the weight loss market. The company reportedly evolved as
Jim Cramer's top pharmaceutical pick for 2025 that receives
FDA nod for multiple myeloma therapy. However, it faced a setback as a COPD drug they developed in partnership with Sanofi failed. Lastly, the company's shareholders approved bylaw amendments at their annual meeting.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 25 Mar 2025 07:00:00 GMT to Sat, 19 Jul 2025 14:41:50 GMT -
Rating 4
- Innovation 8
- Information 8
- Rumor -3
